After 24 weeks of follow-up, IGF-1 levels were reduced to the reference range in 73.8% of patients, but the frequency of DM increased from 32.8% at baseline to 68.9%, explaining hyperglycemia as the most frequent adverse event [44]. Here, IGF1 is linked to Hyperglycemia.